Jim Reddoch, PhD
Dr. Reddoch has led the team at Royalty Pharma that focuses on sourcing and analyzing new investment opportunities and partnerships for over 10 years. Prior to joining Royalty Pharma in 2008, Dr. Reddoch was Head of Healthcare Research at FBR Capital Markets. Previously, Dr. Reddoch was a biotechnology analyst at Bank of America and CIBC World Markets. Dr. Reddoch serves on the board of Avillion, a London-based drug development company funded by Royalty Pharma and other investors, and on Memorial Sloan Kettering Cancer Center’s external review board for its Technology Development Fund. Dr. Reddoch has a BA from Furman University, a PhD in biochemistry and molecular genetics from the University of Alabama, and was a postdoctoral fellow at Yale University.